12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers Viracta Therapeutics (NASDAQ:VIRX) stock increased by 16.8% to $0.68 during Tuesday’s pre-market session. The company’s market cap…
12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers Immutep (NASDAQ:IMMP) stock increased by 15.5% to $2.9 during Wednesday’s pre-market session. The market value of their…
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers INVO Bioscience (NASDAQ:INVO) stock rose 275.0% to $2.85 during Wednesday’s regular session. The market value of their…
Why Is Small-Cap Cancer Drug Developer Viracta Therapeutics Stock Trading Lower On Monday?
Nanatinostat combined with valganciclovir shows promising results in treating relapsed or refractory EBV+ peripheral T-cell lymphoma, demonstrating higher efficacy and tolerability than nanatinostat monotherapy.
Viracta Therapeutics To Present Topline Nana-val Results From Stage 1 of the NAVAL-1 Trial At The 2024 Annual Congress Of The Hematology Society Of Taiwan
Viracta Therapeutics, Inc. (NASDAQ:VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that topline
CACI International To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Viracta Therapeutics Provides Clinical Update And Outlook For 2024
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete enrollment of Stage 1, complete enrollment of Stage 2 anticipated in Q1 2024 and
Viracta Therapeutics Announces Interim Data From Phase 1b/2 Clinical Trial Of Nana-val In Patients With Epstein-Barr Virus-Positive Solid Tumors That Show Confirmed Tumor Responses At Higher Dose Levels
Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher
Viracta Therapeutics: Q3 Earnings Insights
Viracta Therapeutics (NASDAQ:VIRX) reported its Q3 earnings results on Thursday, November 9, 2023 at 08:30 AM. Here’s what…